CORRECTION article

Front. Stroke, 29 January 2024

Sec. Acute Stroke and Interventional Therapies

Volume 3 - 2024 | https://doi.org/10.3389/fstro.2024.1371734

Corrigendum: Adenosine A1R/A3R agonist AST-004 reduces brain infarction in mouse and rat models of acute ischemic stroke

  • 1. Department of Cell Systems and Anatomy, University of Texas Health at San Antonio, San Antonio, TX, United States

  • 2. NeuroVasc Preclinical Services, Inc., Lexington, MA, United States

  • 3. Astrocyte Pharmaceuticals Inc., Cambridge, MA, United States

Article metrics

View details

730

Views

348

Downloads

In the published article, there was an error in the Funding statement. The funding source for coauthor Jeremy J. Stubblefield was not included. Original text: This study received funding from Astrocyte Pharmaceuticals, Inc. The correct Funding statement appears below.

Funding

This study received funding from Astrocyte Pharmaceuticals, Inc. JS was supported by NIH IRACDA training grant K12 GM111726.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

Adora3, stroke treatment, mitochondrial metabolism, ATP, astrocytes

Citation

Fisher ES, Chen Y, Sifuentes MM, Stubblefield JJ, Lozano D, Holstein DM, Ren J, Davenport M, DeRosa N, Chen T, Nickel G, Liston TE and Lechleiter JD (2024) Corrigendum: Adenosine A1R/A3R agonist AST-004 reduces brain infarction in mouse and rat models of acute ischemic stroke. Front. Stroke 3:1371734. doi: 10.3389/fstro.2024.1371734

Received

16 January 2024

Accepted

18 January 2024

Published

29 January 2024

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

3 - 2024

Updates

Copyright

*Correspondence: James D. Lechleiter

†These authors share first authorship

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics